P04-02HR-HPV L1,E1,E2,E6,E7 SEROPOSITIVITY DOES NOT PREDICT ANAL HSIL AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN

04. Immunology
E. Marra 1, M. Siegenbeek Van Heukelom 2, T. Waterboer 3, J. Prins 4, C. Meijer 5, P. Snijders 5, A. King 6, A. Van Eeden 7, W. Brokking 7, H. De Vries 2, M. Schim Van Der Loeff 1.
1Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands, 2Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, 3Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 4Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, 5Department of Pathology, Vrije Universiteit-University Medical Center (VUmc), Amsterdam, the Netherlands, 6Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, 7Department of Internal Medicine, DC klinieken, Amsterdam, the Netherlands

Background / Objectives

High-risk HPV L1 and E6/E7 seropositivity is prospectively associated with anal cancer. We studied L1, E1, E2, E6, E7 seropositivity of high-risk (hr) HPV types as potential predictors of anal high-grade squamous intraepithelial lesions (HSIL) among HIV-positive men who have sex with men (MSM).


Methods

HIV-positive participants of the longitudinal HIV&HPV in MSM (H2M) study who had at least two visits and a high-resolution anoscopy (HRA) after the last H2M visit were included in this analysis. Sera were collected in 2010-2013. Serum antibodies to E6, E7, and L1 proteins of 7 hr-HPV types (16, 18, 31, 33, 45, 52, 58), and serum antibodies to E1 and E2 of HPV16 and HPV18 were analyzed by multiplex serology. Seropositivity was defined as 3 out of 4 positive among E1/E2/E6/E7 for HPV16 and HPV18; and both E6 and E7 positive for each non-HPV16/18-type. Univariable and multivariable logistic regression was used to assess whether hr-HPV seropositivity was predictive of HSIL.


Results

Among 193 MSM (median age 50 years [IQR]:45-56) 60 (31%) were diagnosed with histologically proven anal HSIL: 25 (13%) AIN2 and 35 (18%) AIN3. The median nadir CD4+ was 235 cells/µl (IQR: 150-315 cells/µl), and 94% had an undetectable HIV viral load at time of HRA. Seropositivity for E1, E2, E6, E7 of HPV16 was 7%, 4%, 4%, and 5%, respectively. In total, 0 (0%) were HPV16 three out of four positive for E1/E2/E6/E7, and 0 (0%) HPV18 three out of four positive for E1/E2/E6/E7. E6 and E7 seropositivity for each of the non-HPV16/18 hr-HPV types was 0% (n=0). Type-specific seropositivity as defined above was not associated with HSIL diagnoses.


Conclusion

No association between type-specific hr-HPV seropositivity and anal HSIL was found among HIV-positive MSM. Our analysis shows that (type-specific) hr-HPV seropositivity cannot be used as predictor of HSIL in HIV-positive MSM.


References